Literature DB >> 22121132

IgG4 immune response in Churg-Strauss syndrome.

Augusto Vaglio1, Johanna D Strehl, Bernhard Manger, Federica Maritati, Federico Alberici, Christian Beyer, Jürgen Rech, Renato A Sinico, Francesco Bonatti, Luisita Battistelli, Jörg H W Distler, Georg Schett, Jochen Zwerina.   

Abstract

OBJECTIVE: T-helper type 2 responses are crucial in Churg-Strauss syndrome (CSS) and may enhance the production of IgG4 antibodies. The authors assessed the IgG4 immune response in CSS patients.
METHODS: The authors included 46 consecutive patients with CSS (24 with active and 22 with quiescent disease), 26 with granulomatosis with polyangiitis (GPA, Wegener's), 25 with atopic asthma and 20 healthy controls and determined serum IgG, IgM, IgA, IgE and IgG subclass levels. Tissue infiltration by IgG4 plasma cells was assessed in nine patients with CSS, 10 with GPA, 22 with chronic sinusitis (11 with and 11 without eosinophilia).
RESULTS: IgG4 levels were markedly higher in active CSS patients than in controls (p<0.001 vs all control groups). Serum IgG4 correlated with the number of disease manifestations (r=0.52, p=0.01) and the Birmingham vasculitis activity score (r=0.64, p=0.001). Longitudinal analysis in 12 CSS cases showed that both the IgG4 level and IgG4/IgG ratio dropped during disease remission (p=3×10(-5) and p=6×10(-4), respectively). Tissue analysis did not show an increased IgG4 plasma cell infiltration in CSS biopsies compared with control groups.
CONCLUSIONS: Serum IgG4 levels are markedly elevated in active CSS and correlate with the number of organ manifestations and disease activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22121132     DOI: 10.1136/ard.2011.155382

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   27.973


  39 in total

Review 1.  Chronic Periaortitis: an Update.

Authors:  Alessandra Palmisano; Federica Maritati; Augusto Vaglio
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

Review 2. 

Authors:  Nabil Jakhlal; Anouar Elghazoui; Youness Jabbour; Tarik Karmouni; Khalid Elkhader; Abdellatif Koutani; Ahmed Ibenattya
Journal:  Can Urol Assoc J       Date:  2017-01-12       Impact factor: 1.862

Review 3.  Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis.

Authors:  Paride Fenaroli; Federica Maritati; Augusto Vaglio
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

Review 4.  Eosinophilic Vasculitis.

Authors:  Karen L Vega Villanueva; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2020-01-11       Impact factor: 4.592

Review 5.  [Clinical spectrum of IgG4-related diseases and the connection to rheumatology].

Authors:  F Moosig; J H Schirmer; P Lamprecht; J U Holle
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 6.  Biomarkers in connective tissue diseases.

Authors:  Neelakshi R Jog; Judith A James
Journal:  J Allergy Clin Immunol       Date:  2017-12       Impact factor: 10.793

7.  Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features.

Authors:  Zachary M Dong; Edwin Lin; Michael E Wechsler; Peter F Weller; Amy D Klion; Bruce S Bochner; Don A Delker; Mark W Hazel; Keke Fairfax; Paneez Khoury; Praveen Akuthota; Peter A Merkel; Anne-Marie Dyer; Carol Langford; Ulrich Specks; Gerald J Gleich; Vernon M Chinchilli; Benjamin Raby; Mark Yandell; Frederic Clayton
Journal:  Am J Pathol       Date:  2020-04-03       Impact factor: 4.307

Review 8.  Biomarkers in vasculitis.

Authors:  Paul A Monach
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

Review 9.  [IgG4-related disease].

Authors:  J Loock; B Manger
Journal:  Z Rheumatol       Date:  2013-03       Impact factor: 1.372

10.  Alveolar haemorrhage in eosinophilic granulomatosis and polyangiitis (Churg-Strauss).

Authors:  L Yalakki Jagadeesh; S R Sangle; H Verma; D D'Cruz
Journal:  Clin Rheumatol       Date:  2014-01-25       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.